Safety and eficity of 2.5mg prasugrel therapy in the eldely or low body weight Japanese patients undergoing percutaneous coronary intervention

Trial Profile

Safety and eficity of 2.5mg prasugrel therapy in the eldely or low body weight Japanese patients undergoing percutaneous coronary intervention

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Ischaemic heart disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2017 Status changed from recruiting to completed.
    • 27 May 2016 Status changed from not yet recruiting to recruiting.
    • 27 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top